Scott Gettinger News Today

Yale researchers have potentially found a more effective treatment for non-small cell lung cancer and a better way to identify patients who are suited for these immunotherapies.

Published: Apr 09, 2021 Median Duration of Response Not Reached at 28.1 Months of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma. These data wil...